Erenumab's efficacy and safety for migraine in real-world use

A novel systematic review provided robust evidence supporting the effectiveness and safety of Erenumab in real-world settings. This marks the first meta-analysis focusing on the real-world application of Erenumab, highlighting its potential as a reliable therapeutic option for migraine

Jaime Fernández-Bravo-Rodrigo et al. aimed to evaluate the efficacy and safety of Erenumab in decreasing the intensity and incidence of migraines in real-world scenarios. To look for relevant studies on the impact of Erenumab, a database search of Scopus, Web of Science, PubMed and Cochrane up to December 2023 was performed.

The meta-analysis included 53 studies, revealing significant reductions across multiple parameters at the 3-month mark:

• Monthly Migraine Days: -7.18 days
• Monthly Headache Days: -6.89 days
• Headache Impact Test (HIT-6): -6.97
• Number of Days on Medication: -6.22 days
• Acute Monthly Intake: -15.75
• Pain: -1.71

Also, the benefits of Erenumab grew slightly over 6- and 12-month periods. Response rates revealed that about one-third of patients experienced a greater than 30% reduction in MMD/MHD, one-sixth had over 50%, and 3-4% of patients achieved a 100% response rate. The rates of adverse events were logged as 0.34 at 6 months and 0.43 at 12 months.